IBDEI1RW ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,30134,2)
 ;;=^5000916
 ;;^UTILITY(U,$J,358.3,30135,0)
 ;;=D57.40^^118^1501^15
 ;;^UTILITY(U,$J,358.3,30135,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30135,1,3,0)
 ;;=3^Sickle-cell thalassemia without crisis
 ;;^UTILITY(U,$J,358.3,30135,1,4,0)
 ;;=4^D57.40
 ;;^UTILITY(U,$J,358.3,30135,2)
 ;;=^329908
 ;;^UTILITY(U,$J,358.3,30136,0)
 ;;=D57.419^^118^1501^14
 ;;^UTILITY(U,$J,358.3,30136,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30136,1,3,0)
 ;;=3^Sickle-cell thalassemia with crisis, unspecified
 ;;^UTILITY(U,$J,358.3,30136,1,4,0)
 ;;=4^D57.419
 ;;^UTILITY(U,$J,358.3,30136,2)
 ;;=^5002316
 ;;^UTILITY(U,$J,358.3,30137,0)
 ;;=D56.0^^118^1501^1
 ;;^UTILITY(U,$J,358.3,30137,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30137,1,3,0)
 ;;=3^Alpha thalassemia
 ;;^UTILITY(U,$J,358.3,30137,1,4,0)
 ;;=4^D56.0
 ;;^UTILITY(U,$J,358.3,30137,2)
 ;;=^340494
 ;;^UTILITY(U,$J,358.3,30138,0)
 ;;=D56.1^^118^1501^2
 ;;^UTILITY(U,$J,358.3,30138,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30138,1,3,0)
 ;;=3^Beta thalassemia
 ;;^UTILITY(U,$J,358.3,30138,1,4,0)
 ;;=4^D56.1
 ;;^UTILITY(U,$J,358.3,30138,2)
 ;;=^340495
 ;;^UTILITY(U,$J,358.3,30139,0)
 ;;=D56.2^^118^1501^3
 ;;^UTILITY(U,$J,358.3,30139,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30139,1,3,0)
 ;;=3^Delta-beta thalassemia
 ;;^UTILITY(U,$J,358.3,30139,1,4,0)
 ;;=4^D56.2
 ;;^UTILITY(U,$J,358.3,30139,2)
 ;;=^340496
 ;;^UTILITY(U,$J,358.3,30140,0)
 ;;=D56.3^^118^1501^18
 ;;^UTILITY(U,$J,358.3,30140,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30140,1,3,0)
 ;;=3^Thalassemia minor
 ;;^UTILITY(U,$J,358.3,30140,1,4,0)
 ;;=4^D56.3
 ;;^UTILITY(U,$J,358.3,30140,2)
 ;;=^340497
 ;;^UTILITY(U,$J,358.3,30141,0)
 ;;=D56.5^^118^1501^7
 ;;^UTILITY(U,$J,358.3,30141,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30141,1,3,0)
 ;;=3^Hemoglobin E-beta thalassemia
 ;;^UTILITY(U,$J,358.3,30141,1,4,0)
 ;;=4^D56.5
 ;;^UTILITY(U,$J,358.3,30141,2)
 ;;=^340498
 ;;^UTILITY(U,$J,358.3,30142,0)
 ;;=D56.8^^118^1501^19
 ;;^UTILITY(U,$J,358.3,30142,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30142,1,3,0)
 ;;=3^Thalassemias NEC
 ;;^UTILITY(U,$J,358.3,30142,1,4,0)
 ;;=4^D56.8
 ;;^UTILITY(U,$J,358.3,30142,2)
 ;;=^5002305
 ;;^UTILITY(U,$J,358.3,30143,0)
 ;;=D57.3^^118^1501^16
 ;;^UTILITY(U,$J,358.3,30143,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30143,1,3,0)
 ;;=3^Sickle-cell trait
 ;;^UTILITY(U,$J,358.3,30143,1,4,0)
 ;;=4^D57.3
 ;;^UTILITY(U,$J,358.3,30143,2)
 ;;=^5002313
 ;;^UTILITY(U,$J,358.3,30144,0)
 ;;=D57.1^^118^1501^13
 ;;^UTILITY(U,$J,358.3,30144,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30144,1,3,0)
 ;;=3^Sickle-cell disease without crisis
 ;;^UTILITY(U,$J,358.3,30144,1,4,0)
 ;;=4^D57.1
 ;;^UTILITY(U,$J,358.3,30144,2)
 ;;=^5002309
 ;;^UTILITY(U,$J,358.3,30145,0)
 ;;=D57.02^^118^1501^6
 ;;^UTILITY(U,$J,358.3,30145,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30145,1,3,0)
 ;;=3^Hb-SS disease with splenic sequestration
 ;;^UTILITY(U,$J,358.3,30145,1,4,0)
 ;;=4^D57.02
 ;;^UTILITY(U,$J,358.3,30145,2)
 ;;=^5002308
 ;;^UTILITY(U,$J,358.3,30146,0)
 ;;=D57.01^^118^1501^4
 ;;^UTILITY(U,$J,358.3,30146,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30146,1,3,0)
 ;;=3^Hb-SS disease with acute chest syndrome
 ;;^UTILITY(U,$J,358.3,30146,1,4,0)
 ;;=4^D57.01
 ;;^UTILITY(U,$J,358.3,30146,2)
 ;;=^5002307
 ;;^UTILITY(U,$J,358.3,30147,0)
 ;;=D57.00^^118^1501^5
 ;;^UTILITY(U,$J,358.3,30147,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30147,1,3,0)
 ;;=3^Hb-SS disease with crisis, unspecified
 ;;^UTILITY(U,$J,358.3,30147,1,4,0)
 ;;=4^D57.00
 ;;^UTILITY(U,$J,358.3,30147,2)
 ;;=^5002306
